What is Annex 1 of the European GMP?

Abstract

The 2022 revision of EU GMP Annex 1—effective from 25 August 2023, with certain provisions (e.g., lyophilizer requirements) effective from 25 August 2024—constitutes a major transformation in sterile product manufacturing. This paper presents a structured, in-depth analysis of the key changes, including the emphasis on Quality Risk Management (QRM) and Contamination Control Strategy (CCS), cleanroom classifications, advanced barrier technology (RABS and isolators), and digitalization. It further explores the specific implications for pharmaceutical firms and barrier system manufacturers, drawing on SKAN’s expertise in isolator design, decontamination, and automation to illuminate practical implementation.

 

 

1. Introduction

Sterile medicinal products demand rigorous microbial, particulate, and pyrogen contamination control to guarantee patient safety. EU GMP Annex 1, “Manufacture of Sterile Medicinal Products,” provides regulatory guidance for this purpose. The 2022 revision—crafted collaboratively by the European Commission, PIC/S [12], and WHO [10]—significantly updates expectations, adding clarity, scope, and alignment with modern technological and process capabilities. These revisions underscore risk-based frameworks, contamination control strategies, and advanced barrier technologies [1]. This article unpacks those changes and explores their consequences for the pharmaceutical industry, with concrete examples related to SKAN’s isolator technologies [9].

 

 

2. Overview of EU GMP Annex 1 (2022 Revision)

2.1 Scope and Rationale

Published 25 August 2022 and enforceable from 25 August 2023 (with Section 8.123 phased in August 2024), the revision reflects technological advances and regulatory harmonization across EMA [11], PIC/S [12], and WHO [10]. Highlights include expansion from ~16 to over 50 pages, broader scope including non-sterile areas where contamination risks are relevant [4], and alignment with ISO 14644, ICH Q8/Q9/Q10, and lifecycle management [3].

2.2 Core Principles

– Quality Risk Management (QRM): Mandatory across all EU GMP Annex 1 domains—from facility design to process validation [1].
– Contamination Control Strategy (CCS): Central requirement. CCS must unify risk assessments, premises, equipment, personnel, monitoring, and corrective actions into a coherent, documented plan [3].
– Barrier Technologies: RABS and isolators are strongly encouraged. Their absence requires justification in the CCS [5].

 

Discover secure transfer systems from ABC Transfer®

2.3 Focused Updates

Key areas of change include revised cleanroom classifications [5], PUPSIT requirements [3], stricter gowning [3], enhanced utility controls [2], and encouragement of robotics and digitalization [1][6].

 

 

3. Implications for Drug Manufacturers

3.1 Implementing a CCS under EU GMP Annex 1

Manufacturers must develop a CCS integrating QRM findings, facility design, environmental controls, personnel behavior, equipment maintenance, media fills, and monitoring programs. The CCS must be periodically reviewed in management reviews [1][3].

3.2 PQS Integration

The PQS must embed EU GMP Annex 1 expectations, ensuring linkage between risk assessments and change control decisions, end-to-end traceability, and governance of residual risk justification [7].

3.3 Facility and Barrier Technology

EU GMP Annex 1 strongly favors barrier technologies. RABS and isolators provide enclosed Grade A zones with better contamination control. Manufacturers upgrading older lines to closed RABS achieve compliance with limited investment [5][9].

 

Contact us to discover our solutions

 

3.4 Personal & Training

Sterility assurance emphasizes controlling human contamination. Gowning protocols (socks, goggles, glove sanitization) must be enforced [3]. Operators must be trained and requalified annually per operator and line [8].

3.5 Utilities

Facilities must ensure continuous monitoring (e.g., TOC in WFI), sterilizing filtration for gases, and biofilm control in water systems [2].

3.6 Monitoring, APS & Digitalization

Environmental monitoring includes stricter alert/action levels and continuous monitoring for Grade A zones [8]. APS must be conducted semi-annually per filling line and operator [3]. Automated monitoring is encouraged [6].

 

 

4. Implications for RABS and Isolator Manufacturers

4.1 Regulatory Positioning

EU GMP Annex 1 positions isolators and RABS as favored technologies. Any alternative approaches must be justified [5].

4.2 Design & Engineering Requirements (SKAN insights)

Key requirements include hygienic design, smooth interior surfaces for cleaning, validated VHP decontamination, and automation to reduce human interventions [9].
Differences:
– RABS: Grade B, occasional opening.
– Isolators: Grade D, fully enclosed, VHP decontamination, higher sterility [9].

4.3 Integrity and Airflow

For OEB4/OEB5 isolators: Grade A unidirectional airflow with dual HEPA, validated VHP cycles, and periodic integrity testing [9].

4.4 Containement of Potent Agents

Isolators provide superior containment for toxic/biohazard substances, aligning with biosafety requirements [6][9].

4.5 Automation and Digital Trends

SKAN and others develop robotic and gloveless isolators, automated sampling, and digital integration, reducing human exposure and aligning with Annex 1 [6][9].

4.6 Retrofit and Modular Upgrades

SKAN offers modular isolators and RABS retrofits for existing lines, enabling validated decontamination, glove integrity testing, and compliance without full rebuilds [9].

4.7 Documentation, Validation & CCS Support

Providers must supply validation protocols, FAT/SAT and IQ/OQ/PQ documentation, monitoring instruments, and GMP training packages [9].

 

 

5. Strategic Recommendations & Examples

– Drug Manufacturer: Adopt isolators for high-risk operations; integrate QRM/CCS into PQS [9].
– Barrier System Provider: Prioritize hygienic, validated, automated designs [9].
– Operational Excellence: Replace manual settle plates with automated monitoring [6][9].
– Compliance Roadmap: Use CCS to justify interim solutions [7][9].

 

 

6. Conclusion

The 2022 revision of EU GMP Annex 1 reshapes sterile manufacturing by embedding QRM, CCS, and advanced technologies (RABS, isolators, automation). For drug manufacturers, this means integrated planning, facility upgrades, and continuous monitoring. For barrier system providers like SKAN, it means a pivotal role in enabling compliance through hygienic, decontaminable, automated, and validated solutions. Collaboration between regulators, manufacturers, and technology providers will be essential for ensuring sterility assurance [1][9].

 

 

References

1. ISPE – International Society for Pharmaceutical Engineering. https://ispe.org
2. NSF International. https://nsf.org
3. SciLife. https://scilife.io
4. Public Health Guidance Documents
5. GMP-Verlag Peither AG. https://gmp-verlag.de
6. PharmTech – Pharmaceutical Technology. https://www.pharmtech.com
7. RAPS – Regulatory Affairs Professionals Society. https://raps.org
8. QUALIA BioSafe Tech
9. SKAN AG. https://skan.com
10. World Health Organization (WHO). https://who.int
11. European Medicines Agency (EMA). https://ema.europa.eu
12. PIC/S – Pharmaceutical Inspection Co-operation Scheme. https://picscheme.org